- The report mentions the "All-Weather Quantitative Timing Model" which issued two risk warning signals in the latter half of last week, indicating that the market may still be under pressure in the future [7] - The market is currently in a large box oscillation pattern, with the central position or average cost around 3300-3350 [7] - The current market is in a multi-head arrangement of large-scale moving average systems, and the oscillation during the multi-head arrangement process can often be seen as a process of oscillation and accumulation [7] - The current adjustment appears after three waves of upward movement at the daily level, coinciding with the upper edge of the oscillation center, and there is a daily level top divergence and daily TD9 count, indicating a potential adjustment period of about 3 weeks based on the common 0.382 time retracement ratio characteristic [7] Quantitative Models and Construction Methods 1. **Model Name**: All-Weather Quantitative Timing Model - **Model Construction Idea**: The model aims to provide risk warning signals based on market conditions and technical indicators [7] - **Model Construction Process**: The model uses various technical indicators such as the daily level top divergence and TD9 count to identify potential market adjustments. The model also considers the 0.382 time retracement ratio to estimate the adjustment period [7] - **Model Evaluation**: The model effectively issued risk warning signals, indicating its potential usefulness in predicting market pressure [7] Model Backtesting Results 1. **All-Weather Quantitative Timing Model**: The model issued two risk warning signals in the latter half of last week, suggesting that the market may still be under pressure [7] Quantitative Factors and Construction Methods - No specific quantitative factors were detailed in the provided content Factor Backtesting Results - No specific quantitative factors were detailed in the provided content

Investment Rating - The report maintains an investment rating of "Outperform-A" for the biopharmaceutical sector [6]. Core Insights - The biopharmaceutical sector is experiencing rapid growth, particularly with the inclusion of several innovative drugs into the national medical insurance directory, leading to increased hospital admissions [2][19]. - Notable increases in hospital admissions for specific drugs have been observed, such as the rapid uptake of drugs like Budesonide enteric-coated capsules and monoclonal antibodies from Kangfang Biotech [2][19]. - The report highlights significant clinical approvals and applications for new drugs, indicating a robust pipeline and ongoing innovation within the industry [3][4][23]. Summary by Sections 1. Weekly New Drug Market Review - From June 9 to June 13, 2025, the top five companies in the new drug sector by stock price increase were Beihai Kangcheng-B (up 118.12%), Oconview Biotech-B (up 28.59%), Junshengtai Pharmaceutical-B (up 23.75%), WuXi AppTec-B (up 23.63%), and Gilead Sciences-B (up 23.40%) [1][13]. - The top five companies with stock price declines included Sangamo Therapeutics (-7.41%), Nossland (-7.14%), Yiming Oncology-B (-6.10%), Hualing Pharmaceutical-B (-4.38%), and Yongtai Biotech-B (-3.48%) [1][13]. 2. Key Industry Analysis - The National Healthcare Security Administration updated the hospital admission data for innovative drugs included in the medical insurance directory as of April 2025, showing rapid hospital admissions for several newly included domestic innovative drugs [2][19]. - The drugs with the fastest growth in hospital admissions compared to March 2025 include Budesonide enteric-coated capsules, Kangfang Biotech's monoclonal antibodies, and others [2][19]. 3. New Drug Application Approvals & Acceptances - Two new drug or new indication applications were approved this week, including the inhalation solution of Revinase and the injection of Pembrolizumab [23][24]. - Nine new drug applications were accepted, including Bevacizumab intravitreal injection and various insulin formulations [23][24]. 4. New Drug Clinical Application Approvals & Acceptances - A total of 45 new drug clinical applications were approved this week, with six new drug clinical applications accepted [4]. 5. Domestic Market Key Events TOP3 - Lepu Biotech's new drug MRG007 was approved for clinical trials, targeting locally advanced or metastatic solid tumors [5]. - Nocera Biotech presented multiple drug research data at the European Hematology Association annual meeting, showing significant efficacy in treating various blood diseases [5][9]. 6. Overseas Market Key Events TOP3 - Bristol-Myers Squibb announced positive results for Deucravacitinib in a Phase III trial for psoriatic arthritis, significantly improving patient symptoms [10]. - Nuvation Bio's Ibtrozi received FDA approval for treating ROS1-positive non-small cell lung cancer, demonstrating high response rates and good tolerability [10]. - Merck's enlictide decanoate showed positive results in two Phase III trials, potentially becoming the first oral PCSK9 inhibitor approved in the U.S. [10].

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" [6] Core Insights - Quantum technology is expected to bring disruptive innovations in computing power, driving demand for quantum secure communication and post-quantum cryptography [12] - Major advancements in quantum computing have been made by leading companies, indicating a competitive landscape in the industry [13][14] - The establishment of dedicated quantum research centers by companies like NVIDIA signifies a strategic shift towards integrating quantum computing with AI [15][16] Summary by Sections 1. Industry Insights - Quantum computing is based on quantum mechanics, utilizing quantum bits for processing, which offers unparalleled information capacity and parallel processing capabilities [12] - The emergence of quantum secure communication and post-quantum cryptography is a response to the potential threats posed by quantum computing to traditional encryption methods [12] 2. Chip Developments - Microsoft launched the Majorana 1 quantum chip, while Amazon introduced the Ocelot chip, which significantly reduces error correction overhead [13] - D-Wave's Advantage2™ system marks a pivotal shift from laboratory to enterprise-level applications, featuring over 4,400 qubits [13] - IBM's roadmap includes the release of a large-scale fault-tolerant quantum computer by 2029, expected to outperform current systems by 20,000 times [13] 3. Algorithmic Advancements - D-Wave demonstrated quantum superiority by solving a magnetic material simulation problem in 20 minutes, a task that would take traditional supercomputers nearly 1 million years [14] - Google's research indicates that a million noisy qubits could crack RSA-2048 encryption in a week, significantly shortening the traditional security period [14] 4. Industry Participation - NVIDIA's establishment of the Accelerated Quantum Research Center aims to integrate quantum hardware with AI supercomputing [15] - The CEO of NVIDIA has shifted his stance on quantum computing, predicting significant advancements in the coming years [16] 5. Market Performance - The computer industry index decreased by 2.25%, underperforming compared to major indices [17] - The report highlights the need to monitor long-term trends in AI, robotics, and self-controllable industries [21]

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" [8] Core Insights - The Thai government is advancing legislation for gambling laws, which is expected to further stimulate local tourism consumption [1] - The entertainment complex project is projected to attract at least 100 billion THB in private sector investment, with GDP growth expected to increase by 0.23% during construction and 0.2-0.8% post-opening [2] - The project is anticipated to generate 10-20 billion THB in tourism revenue and create 9,000-15,000 jobs, enhancing the local tourism industry [2] - The government plans to issue a limited number of large investment licenses, focusing on major integrated development projects rather than multiple smaller licenses [3] - Access for local residents will be controlled through a negative list approach, with the primary customer base being foreign tourists [4] - The Thai government is currently in discussions with four major international resort operators, including Wynn and MGM, showing significant interest in investing in Thai gambling [5] - The report suggests focusing on MGM China as a potential investment opportunity [6] Summary by Sections - **Investment Rating**: The report maintains an "Outperform the Market - A" rating, indicating expected returns exceeding the market index [8] - **Economic Impact**: The entertainment complex is expected to significantly boost tourism and GDP, with a projected increase in tourist spending to 22,300 THB per person per trip [2] - **Regulatory Framework**: The Thai government will issue a limited number of licenses and control project locations to maximize economic spillover effects [3] - **Market Access**: Local access will be restricted for residents, aligning with practices in Singapore and South Korea [4] - **Operator Engagement**: The government is engaging with major international operators to facilitate investment in the gambling sector [5]

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the pharmaceutical industry [8]. Core Insights - The overall retail sales of traditional Chinese medicine (TCM) in pharmacies showed a year-on-year decline in Q1 2025, indicating pressure on the market [3][19]. - The report highlights stable rankings among major products in various therapeutic areas despite the overall sales decline [18]. Summary by Sections Overall Situation - The retail sales of TCM in pharmacies increased from 143.9 billion yuan in 2017 to 168 billion yuan in 2024, with a compound annual growth rate (CAGR) of 2.23%. However, Q1 2025 sales were 41.2 billion yuan, down 7.67% year-on-year, attributed to regulatory pressures and consumer downgrade [3][19]. Therapeutic Areas - **Cold and Heat Relief**: Sales decreased by 6.90% year-on-year in Q1 2025, with sales reaching 7.3 billion yuan, influenced by lower respiratory disease cases compared to the previous year [4][22]. - **Nutritional and Health Supplements**: Sales slightly declined by 1.01% year-on-year in Q1 2025, totaling 5.8 billion yuan, impacted by consumer downgrade and high sales in the previous year [5][25]. - **Cardiovascular Health**: Sales showed a slight decline of 2.98% year-on-year in Q1 2025, with sales at 10.4 billion yuan, reflecting stable market demand [6][28]. - **Musculoskeletal Health**: Sales increased by 0.68% year-on-year in Q1 2025, reaching 3.7 billion yuan, indicating long-term growth potential due to aging demographics [14][31]. - **Gastrointestinal Health**: Sales grew by 7.13% year-on-year in Q1 2025, totaling 16 billion yuan, reflecting a recovery in demand [34]. - **Cough and Phlegm Relief**: Sales dropped significantly by 26.80% year-on-year in Q1 2025, amounting to 4.8 billion yuan, primarily due to a high base effect from the previous year [15][37].

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" [6] Core Viewpoints - The retail pharmacy industry is experiencing a decline in sales at physical stores, with a year-on-year decrease noted in May 2025. However, the structure of listed pharmacy stores is gradually optimizing, which is expected to lead to stable growth in performance [3][13] - In May 2025, the average daily sales per store in physical pharmacies were 2,769.8 yuan, reflecting a year-on-year decline of 3.09%. The average order volume per store increased by 4.57%, while the average transaction value decreased by 7.21% [4][15] - The retail pharmacy sector has seen a concentration increase, with the top six listed pharmacies holding a market share of approximately 17.94%. Despite a year-on-year revenue decline of 1.77% for the overall retail pharmacy market in 2024, these pharmacies are expected to achieve growth due to steady store expansion [20][21] Summary by Sections Macro Dimension - The market size of domestic physical pharmacies in 2024 was 611.9 billion yuan, showing a year-on-year decrease of 1.77% due to factors such as declining transaction values and reduced product offerings [14] - In May 2025, the average daily sales per store in physical pharmacies were 2,769.8 yuan, which is a 3.09% year-on-year decline. The average order volume per store increased by 4.57%, while the average transaction value decreased by 7.21% [15] Micro Dimension - The structure of listed pharmacy stores is gradually optimizing, with several companies maintaining a high proportion of new store openings. In 2024, the proportion of new stores for major pharmacies was as follows: Yifeng Pharmacy (31%), Dazhenglin (25%), Laobaixing (31%), Yixintang (15%), Jianzhijia (38%), and Shuyupingmin (34%) [5][25] - The retail pharmacy industry is witnessing a further increase in concentration, with the top six listed pharmacies expected to achieve better-than-industry growth due to their steady expansion [20][21]

Investment Rating - The report does not explicitly provide an investment rating for the industry Core Insights - The construction industry is experiencing operational pressure due to declining real estate demand and local fiscal constraints, with a projected revenue decline of 3.81% year-on-year for 2024 and a net profit decline of 14.59% [2][16] - Non-traditional construction sectors, such as chemical engineering and international engineering, are showing resilience and growth, with chemical engineering revenue increasing by 4.43% year-on-year in 2024 [2][25] - The eight major state-owned enterprises (SOEs) in the construction sector have seen a slight decrease in revenue and profit, but their overseas business is performing well, with a 10.05% increase in overseas revenue in 2024 [3][41] Summary by Sections Revenue and Performance - The construction industry is under pressure, with a total revenue of 8.71 trillion yuan in 2024, down 3.81% year-on-year, and a net profit of 1.83 trillion yuan, down 14.59% [2][19] - The first quarter of 2025 saw a revenue decline of 6.17% year-on-year, attributed to seasonal factors and delayed project commencement [2][17] - The eight major SOEs accounted for approximately 80.31% of the construction sector's revenue, with a total revenue of about 7 trillion yuan in 2024, down 3.55% year-on-year [3][33] Profitability - The overall gross margin for the construction industry remained stable at 10.92% in 2024, with improvements noted in international engineering and chemical engineering sectors [4][42] - The net profit margin decreased to 2.62% in 2024, primarily due to increased expense ratios and impairment losses [4][19] - Return on equity (ROE) for the industry fell to 7.29%, with international engineering leading at 10.78% [7][19] Cash Flow and Debt - The operating cash flow for the construction industry decreased by 31.60% year-on-year in 2024, totaling 1.12 trillion yuan [8][19] - The debt ratio for the industry increased to 76.84% in 2024, indicating rising financial leverage [19][42] Investment Outlook - The fiscal policy for 2025 is expected to be positive, with significant government investment planned, including a deficit target of 5.66 trillion yuan and new special bonds totaling 4.4 trillion yuan [24][25] - The concentration of the industry is increasing, with major SOEs expected to enhance their competitive edge [9][24] - The overseas business of construction SOEs is anticipated to continue growing, with a focus on international projects along the Belt and Road Initiative [10][41]

Export and Trade - In May, exports decreased by 4.8% year-on-year, a decline of 3.3 percentage points from April, indicating weakened trade momentum[4] - Exports to the US fell sharply from -21.0% in April to -34.5% in May, while exports to ASEAN and India also declined significantly[5] - Exports to the EU increased from 8.3% in April to 12.0% in May, suggesting a growing reliance on the European market amid tariff impacts[5] Inflation and Price Pressure - The Producer Price Index (PPI) in May showed a year-on-year decline of 3.3%, continuing a downward trend[8] - Consumer Price Index (CPI) remained flat at -0.1% year-on-year in May, indicating persistent weak demand and price pressures[11] - Industrial product prices are experiencing deeper declines due to insufficient terminal demand and strong manufacturing supply[14] Economic Outlook - The overall economic growth rate may experience a slight slowdown in Q2, influenced by diminishing export momentum and increasing price pressures[14] - The risk appetite in the equity market is rising, supported by potential tariff reductions in US-China negotiations and stable domestic economic performance[17] - The central bank's recent actions, including a 1 trillion yuan reverse repo operation, reflect a strong intention to stabilize liquidity in the financial system[18]

Investment Rating - The report maintains an investment rating of "Leading the Market - A" [7] Core Viewpoints - The report highlights a slowdown in sales recovery, with urban renewal policies gaining momentum. The Ministry of Finance and the Ministry of Housing and Urban-Rural Development announced over 20 cities, including Beijing and Tianjin, will receive more than 20 billion yuan in central financial support for urban renewal projects in the coming years [1] - The report suggests that the sales growth of new and second-hand homes in core cities has further slowed down, necessitating stronger real estate control policies to stabilize the market [1] - It recommends focusing on distressed real estate companies that may experience a turnaround, such as China Vanke and New Town Holdings, as well as leading companies maintaining land acquisition intensity like China Merchants Shekou and Poly Developments [1] Sales Review (5.31-6.6) - A total of 13,000 units were sold across 32 monitored cities, a week-on-week decrease of 37.3%. Cumulatively, 349,000 units have been sold in 2025, a year-on-year decrease of 3.8% [2][13] - In first-tier cities, 3,744 units were sold, down 41.5% week-on-week, with a cumulative total of 101,000 units sold in 2025, reflecting a year-on-year increase of 12.6% [2][13] - Second-tier cities saw 7,820 units sold, down 35% week-on-week, with a cumulative total of 207,000 units sold in 2025, a year-on-year decrease of 10.2% [2][13] - Third-tier cities recorded 1,256 units sold, down 37.6% week-on-week, with a cumulative total of 42,000 units sold in 2025, a year-on-year decrease of 3.8% [2][13] Land Supply (5.26-6.1) - The planned construction area for residential land supply across 100 cities is 9.14 million square meters, with a cumulative supply of 89.1 million square meters in 2025, reflecting a year-on-year decrease of 11.6% [3][21] - The average floor price for land supply across 100 cities is 7,119 yuan per square meter, with a recent four-week average of 6,092 yuan per square meter, showing a week-on-week decrease of 4% and a year-on-year increase of 20.1% [3][21] Land Transaction (5.26-6.1) - The planned construction area for residential land transactions across 100 cities is 4.26 million square meters, with a cumulative total of 73.97 million square meters sold in 2025, reflecting a year-on-year increase of 1.9% [4][46] - The average transaction floor price for residential land across 100 cities is 5,455 yuan per square meter, down 16.6% week-on-week but up 5.1% year-on-year, with an overall premium rate of 5.5% [4][46]

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" [5] Core Insights - Stablecoins are positioned as the cornerstone of a new financial system centered around blockchain technology, addressing limitations of traditional financial services such as high costs, inefficiencies, and lack of inclusivity [11][12] - Circle is the second-largest stablecoin issuer globally, with a circulating supply of nearly $60 billion for USDC, capturing a market share of 29% as of March 31, 2025 [2][17] - The future applications of stablecoins are primarily in two areas: payment scenarios focusing on cross-border payments and trading scenarios centered on decentralized finance (DeFi) and real-world asset (RWA) tokenization [16][39] Summary by Sections Industry Overview - Traditional financial systems face challenges including high transaction costs, inefficiencies in fund transfers, regulatory constraints, and limited access for underserved populations [11] - Blockchain technology offers a decentralized, transparent, and efficient alternative, enabling rapid transactions and significantly lower costs [12] Circle's Position - Circle's USDC has seen substantial growth, with the number of active wallets increasing from 1.3 million in Q1 2022 to 4.883 million in Q1 2025 [2][20] - The company maintains a strong compliance framework, with its stablecoin redeemable 1:1 with USD and backed by reserve assets [21][22] Revenue Generation - Circle's primary revenue source is derived from reserve income, which accounted for 95%-99% of total revenue from 2022 to 2024, closely tied to the size of reserve assets and macro interest rates [2][24] - The company is diversifying its revenue streams through on-chain developer services, tokenized funds, and other innovative financial products [3][25] Future Growth Opportunities - Circle is expanding its product offerings, including Circle Wallets, Circle Contracts, and Circle Paymaster, to enhance user experience and facilitate seamless transactions across different blockchain networks [26][29][32] - The acquisition of Hashnote and the launch of the USYC tokenized multi-asset fund represent strategic moves to enhance interoperability and liquidity in the digital asset space [33] Market Trends - The report highlights the potential for stablecoins to disrupt traditional financial systems and emphasizes the importance of partnerships with entities like Coinbase to drive growth and market penetration [36][39] - The overall performance of the computer industry, including segments like fintech and AI, has shown resilience and growth, indicating a favorable environment for companies like Circle [40][44]